184 related articles for article (PubMed ID: 28789944)
1. Prioritization of natural compounds against mycobacterium tuberculosis 3-dehydroquinate dehydratase: A combined in-silico and in-vitro study.
Lone MY; Athar M; Gupta VK; Jha PC
Biochem Biophys Res Commun; 2017 Sep; 491(4):1105-1111. PubMed ID: 28789944
[TBL] [Abstract][Full Text] [Related]
2. Structure-based virtual screening as a tool for the identification of novel inhibitors against Mycobacterium tuberculosis 3-dehydroquinate dehydratase.
Petersen GO; Saxena S; Renuka J; Soni V; Yogeeswari P; Santos DS; Bizarro CV; Sriram D
J Mol Graph Model; 2015 Jul; 60():124-31. PubMed ID: 26043661
[TBL] [Abstract][Full Text] [Related]
3. Identification of Mycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors: A combined in-silico and in-vitro analysis.
Lone MY; Athar M; Gupta VK; Jha PC
J Mol Graph Model; 2017 Sep; 76():172-180. PubMed ID: 28734205
[TBL] [Abstract][Full Text] [Related]
4. Structure-and-mechanism-based design and discovery of type II Mycobacterium tuberculosis dehydroquinate dehydratase inhibitors.
Yao Y; Li ZS
Curr Top Med Chem; 2014; 14(1):51-63. PubMed ID: 24236726
[TBL] [Abstract][Full Text] [Related]
5. A 96-well microtiter plate assay for high-throughput screening of Mycobacterium tuberculosis dTDP-d-glucose 4,6-dehydratase inhibitors.
Shi X; Sha S; Liu L; Li X; Ma Y
Anal Biochem; 2016 Apr; 498():53-8. PubMed ID: 26778528
[TBL] [Abstract][Full Text] [Related]
6. Elucidation of Mycobacterium tuberculosis type II dehydroquinase inhibitors using a fragment elaboration strategy.
Tran AT; West NP; Britton WJ; Payne RJ
ChemMedChem; 2012 Jun; 7(6):1031-43. PubMed ID: 22461418
[TBL] [Abstract][Full Text] [Related]
7. Toward antituberculosis drugs: in silico screening of synthetic compounds against Mycobacterium tuberculosisl,d-transpeptidase 2.
Billones JB; Carrillo MC; Organo VG; Macalino SJ; Sy JB; Emnacen IA; Clavio NA; Concepcion GP
Drug Des Devel Ther; 2016; 10():1147-57. PubMed ID: 27042006
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and characterization of dual inhibitors against new targets FabG4 and HtdX of Mycobacterium tuberculosis.
Banerjee DR; Biswas R; Das AK; Basak A
Eur J Med Chem; 2015 Jul; 100():223-34. PubMed ID: 26092447
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations.
Saxena S; Abdullah M; Sriram D; Guruprasad L
J Biomol Struct Dyn; 2018 Sep; 36(12):3184-3198. PubMed ID: 28948866
[TBL] [Abstract][Full Text] [Related]
10. Molecular modeling of a series of dehydroquinate dehydratase type II inhibitors of Mycobacterium tuberculosis and design of new binders.
Miranda PHS; Lourenço EMG; Morais AMS; de Oliveira PIC; Silverio PSSN; Jordão AK; Barbosa EG
Mol Divers; 2021 Feb; 25(1):1-12. PubMed ID: 31820222
[TBL] [Abstract][Full Text] [Related]
11. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.
Kumar S; Mehra R; Sharma S; Bokolia NP; Raina D; Nargotra A; Singh PP; Khan IA
Tuberculosis (Edinb); 2018 Jan; 108():56-63. PubMed ID: 29523328
[TBL] [Abstract][Full Text] [Related]
12. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase.
Baig IA; Moon JY; Lee SC; Ryoo SW; Yoon MY
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1338-50. PubMed ID: 25988243
[TBL] [Abstract][Full Text] [Related]
13. Design and structural analysis of aromatic inhibitors of type II dehydroquinase from Mycobacterium tuberculosis.
Howard NI; Dias MV; Peyrot F; Chen L; Schmidt MF; Blundell TL; Abell C
ChemMedChem; 2015 Jan; 10(1):116-33. PubMed ID: 25234229
[TBL] [Abstract][Full Text] [Related]
14. A prodrug approach for improving antituberculosis activity of potent Mycobacterium tuberculosis type II dehydroquinase inhibitors.
Tizón L; Otero JM; Prazeres VF; Llamas-Saiz AL; Fox GC; van Raaij MJ; Lamb H; Hawkins AR; Ainsa JA; Castedo L; González-Bello C
J Med Chem; 2011 Sep; 54(17):6063-84. PubMed ID: 21780742
[TBL] [Abstract][Full Text] [Related]
15. In silico comparison of antimycobacterial natural products with known antituberculosis drugs.
Espinoza-Moraga M; Njuguna NM; Mugumbate G; Caballero J; Chibale K
J Chem Inf Model; 2013 Mar; 53(3):649-60. PubMed ID: 23410241
[TBL] [Abstract][Full Text] [Related]
16. Benzothiazole Derivative as a Novel Mycobacterium tuberculosis Shikimate Kinase Inhibitor: Identification and Elucidation of Its Allosteric Mode of Inhibition.
Mehra R; Rajput VS; Gupta M; Chib R; Kumar A; Wazir P; Khan IA; Nargotra A
J Chem Inf Model; 2016 May; 56(5):930-40. PubMed ID: 27149193
[TBL] [Abstract][Full Text] [Related]
17. Structural insight into Mycobacterium tuberculosis maltosyl transferase inhibitors: pharmacophore-based virtual screening, docking, and molecular dynamics simulations.
Sengupta S; Roy D; Bandyopadhyay S
J Biomol Struct Dyn; 2015; 33(12):2655-66. PubMed ID: 25669125
[TBL] [Abstract][Full Text] [Related]
18. Structure-based screening and molecular dynamics simulations offer novel natural compounds as potential inhibitors of Mycobacterium tuberculosis isocitrate lyase.
Shukla R; Shukla H; Sonkar A; Pandey T; Tripathi T
J Biomol Struct Dyn; 2018 Jun; 36(8):2045-2057. PubMed ID: 28605994
[TBL] [Abstract][Full Text] [Related]
19. Screening of Antitubercular Compound Library Identifies Inhibitors of Mur Enzymes in
Eniyan K; Rani J; Ramachandran S; Bhat R; Khan IA; Bajpai U
SLAS Discov; 2020 Jan; 25(1):70-78. PubMed ID: 31597510
[TBL] [Abstract][Full Text] [Related]
20. Fluorescently labelled thioacetazone for detecting the interaction with
Singh BK; Singha M; Basak S; Biswas R; Das AK; Basak A
Org Biomol Chem; 2022 Feb; 20(7):1444-1452. PubMed ID: 35084426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
